Megace (Megestrol Acetate)

Megestrol acetate binds to progesterone receptors and exerts glucocorticoid activity. This dual action increases appetite and nitrogen retention while interfering with estrogen‑driven growth in hormone‑sensitive tumors, providing both metabolic and antineoplastic benefits.

The dose of Megace is individualized by the prescribing clinician based on the specific indication, patient weight, and clinical response. Dosage regimens can vary widely, and the prescriber determines the appropriate strength and schedule.

Safety data for megestrol acetate in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk.

To request Megace, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Megace is often compared with other appetite stimulants such as dronabinol or corticosteroids. Unlike cannabinoids, Megace provides a progestogenic and glucocorticoid effect that can also address hormone‑responsive cancers, while corticosteroids may have a broader immunosuppressive profile but lack the specific antineoplastic activity of megestrol acetate.

Megace tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity.

Megace is taken orally, usually as a tablet, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the medication should be taken with meals.

The most serious adverse events include thromboembolic complications (such as deep‑vein thrombosis or pulmonary embolism), adrenal insufficiency from prolonged glucocorticoid activity, and severe hyperglycemia or Cushingoid changes. Patients should be monitored regularly for signs of these conditions.

Megace should be avoided in individuals with known hypersensitivity to megestrol acetate, active uncontrolled infections, a history of thromboembolic disease, severe hepatic impairment, or in pregnant women unless clearly indicated. Clinicians must assess each patient’s risk profile before initiating therapy.